Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Benjamin Jackson Sells 13,272 Shares

Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) General Counsel Benjamin Jackson sold 13,272 shares of the business's stock in a transaction on Friday, January 10th. The stock was sold at an average price of $7.42, for a total value of $98,478.24. Following the transaction, the general counsel now directly owns 128,473 shares of the company's stock, valued at $953,269.66. The trade was a 9.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Benjamin Jackson also recently made the following trade(s):

• On Monday, January 13th, Benjamin Jackson sold 7,912 shares of Sera Prognostics stock. The shares were sold at an average price of $6.38, for a total value of $50,478.56.
• On Monday, November 11th, Benjamin Jackson sold 4,727 shares of Sera Prognostics stock. The stock was sold at an average price of $7.32, for a total value of $34,601.64.

Sera Prognostics Trading Up 0.6 %

NASDAQ:SERA traded up $0.04 during mid-day trading on Tuesday, hitting $6.37. The stock had a trading volume of 134,610 shares, compared to its average volume of 143,614. Sera Prognostics, Inc. has a twelve month low of $4.98 and a twelve month high of $12.35. The company has a market capitalization of $215.13 million, a PE ratio of -6.43 and a beta of 0.86. The stock has a 50-day simple moving average of $7.44 and a two-hundred day simple moving average of $7.31.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.09 million. During the same quarter in the previous year, the business earned ($0.23) earnings per share. Sell-side analysts predict that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Institutional Trading of Sera Prognostics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Quest Partners LLC boosted its stake in Sera Prognostics by 533.5% during the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company's stock worth $50,000 after purchasing an additional 5,415 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Sera Prognostics in the third quarter valued at about $78,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Sera Prognostics during the second quarter worth about $68,000. Prime Capital Investment Advisors LLC purchased a new position in shares of Sera Prognostics during the third quarter worth about $104,000. Finally, Pallas Capital Advisors LLC purchased a new position in shares of Sera Prognostics during the fourth quarter worth about $113,000. Institutional investors and hedge funds own 54.64% of the company's stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.